Intercept Pharmaceuticals (ICPT) PT Lowered to $34 at Needham & Company; 'Low Visibility on Regulatory Path Forward in NASH'
Tweet Send to a Friend
Needham & Company analyst Joseph Stringer lowered the price target on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
